Jiong Zhao

USPTO Granted Patents = 12 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 21(Granted Patents)

Location History:

Chicago, IL (US) (2022 - 2023)
Urbana, IL (US) (2018 - 2024)

Company Filing History:

11 out of 2,341

University of Illinois

patents

1 out of 48

G1 Therapeutics, Inc.

patents

Years Active: 2018-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12295939 - Substituted benzothiophene analogs as selective estrogen receptor degraders (2025-05-13),

2. 12054469 - Benzothiophene-based selective estrogen receptor downregulator compounds (2024-08-06),

3. 11840533 - Pyridinone-based epigenetic modifiers and uses thereof (2023-12-12),

4. 11759450 - Substituted benzothiophene analogs as selective estrogen receptor degraders (2023-09-19),

5. 11447461 - Benzothiophene-based selective estrogen receptor downregulators (2022-09-20),

6. 11364222 - Combination therapy for treatment of cancer (2022-06-21),

7. 11332466 - Pyridinone-based epigenetic modifiers and uses thereof (2022-05-17),

8. 11072595 - Benzothiophene-based selective estrogen receptor downregulator compounds (2021-07-27),

9. 10807964 - Benzothiophene-based selective estrogen receptor downregulators (2020-10-20),

10. 10703747 - Benzothiophene-based selective mixed estrogen receptor downregulators (2020-07-07),

11. 10377735 - Benzothiophene-based selective estrogen receptor downregulators (2019-08-13),

12. 10118910 - Benzothiophene-based selective estrogen receptor downregulators (2018-11-06),

Title: Jiong Zhao: Innovator in Estrogen Receptor Research

Introduction

Jiong Zhao is a prominent inventor based in Urbana, IL (US), known for his significant contributions to the field of estrogen receptor research. With a total of 12 patents, Zhao has made remarkable strides in developing innovative compounds that target estrogen-related medical disorders.

Latest Patents

Among his latest patents, Zhao has developed substituted benzothiophene analogs as selective estrogen receptor degraders. This invention relates to compounds that serve as selective degraders of the estrogen receptor, along with methods for their synthesis and pharmaceutical compositions. These compounds are particularly useful in treating clinical conditions associated with the estrogen receptor, such as breast cancer and osteoporosis. Another notable patent involves benzothiophene-based selective estrogen receptor downregulator compounds, which are designed to treat estrogen-related medical disorders.

Career Highlights

Zhao has worked with esteemed institutions, including the University of Illinois and G1 Therapeutics, Inc. His work has been instrumental in advancing the understanding and treatment of estrogen-related conditions, showcasing his dedication to medical innovation.

Collaborations

Zhao has collaborated with notable colleagues, including Gregory R. Thatcher and Rui Xiong, further enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Jiong Zhao's innovative work in the field of estrogen receptor research has led to significant advancements in medical treatments. His contributions continue to influence the landscape of pharmaceutical development and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.